Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Jazz Pharma Plc (JAZZ)

Jazz Pharma Plc (JAZZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
3 Small-Cap Stocks That Fall Short

3 Small-Cap Stocks That Fall Short

JAZZ : 171.16 (+0.20%)
MSM : 86.13 (+1.72%)
CHPT : 6.89 (-3.37%)
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer

Mr. Riga brings over 25 years of commercial and operational experience with proven success leading transformative corporate development strategies and transactions

JAZZ : 171.16 (+0.20%)
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit

Positive Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line metastatic GEA and Ziihera plus chemotherapy to replace trastuzumab as the new...

JAZZ : 171.16 (+0.20%)
Reflecting On Pharmaceuticals Stocks’ Q3 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ)

Reflecting On Pharmaceuticals Stocks’ Q3 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ)

JAZZ : 171.16 (+0.20%)
3 Mid-Cap Stocks with Warning Signs

3 Mid-Cap Stocks with Warning Signs

GL : 139.82 (-1.82%)
JAZZ : 171.16 (+0.20%)
CNC : 47.27 (+2.38%)
3 Reasons JAZZ is Risky and 1 Stock to Buy Instead

3 Reasons JAZZ is Risky and 1 Stock to Buy Instead

JAZZ : 171.16 (+0.20%)
Jazz Pharmaceuticals to Participate in Upcoming Investor Events

DUBLIN , Dec. 17, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following investor events:

JAZZ : 171.16 (+0.20%)
3 Value Stocks We’re Skeptical Of

3 Value Stocks We’re Skeptical Of

JAZZ : 171.16 (+0.20%)
BAND : 13.53 (-0.15%)
FDX : 313.16 (-0.12%)
Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting

New interim results from the EpiCom trial, a prospective evaluation of behavioral outcomes in patients with tuberous sclerosis complex, suggest improvements in non-seizure outcomes

JAZZ : 171.16 (+0.20%)
3 Healthcare Stocks We’re Skeptical Of

3 Healthcare Stocks We’re Skeptical Of

JAZZ : 171.16 (+0.20%)
AZTA : 39.91 (+1.04%)
AMRX : 13.19 (-0.45%)

Barchart Exclusives

As Citigroup Slashes Jobs, Should You Buy, Sell, or Hold the Dividend Stock Yielding 2%?
As part of a broader plan to cut 20,000 roles by the end of the year, Citigroup announced 1,000 cuts this week. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar